Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2016

Y. Peng Loh's Biography

Y. Peng Loh, Chief and Senior Investigator, Section on Cellular Neurobiology, Eunice Kennedy Shriver National Institute of Child health and Human Development, National Institutes of Health (NIH)

Dr. Y. Peng Loh is the Chief, and Senior Investigator in the Section on Cellular Neurobiology, NICHD, NIH, USA. She received her PhD from the University of Pennsylvania in Molecular Biology and did postdoctoral studies at NIH in Molecular and Cellular Neuroscience. Her laboratory research over the last 8 years focuses on two areas: First, the new role of carboxypeptidase E (CPE, now also named NF-a1) as a trophic factor in neuroprotection, depression and stem cell differentiation. Secondly, she investigates the important roles discovered in her laboratory, of CPE and a splice variant of the CPE gene (CPE-?N) in tumor growth, survival and metastasis. CPE/CPE-?N is being developed as a tumor tissue biomarker for predicting future recurrence/metastasis, especially in patients with early stage cancers of various types, as well as for blood-based (circulating exosome) screening of high risk patients for early detection of cancer. She has published more than 250 papers in reputable journals and book chapters and is on the editorial board of several journals. She has lectured world-wide, and received many prestigious awards including the FASEB Excellence in Science Award, NIH Director’s awards for Science and the Anita Roberts Distinguished Woman Scientist Award.

Y. Peng Loh Image

Carboxypeptidase E: A Biomarker for Detection of Cancer in Circulating Exosomes

Friday, 30 September 2016 at 15:00

Add to Calendar ▼2016-09-30 15:00:002016-09-30 16:00:00Europe/LondonCarboxypeptidase E: A Biomarker for Detection of Cancer in Circulating ExosomesLiquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California,

Tumor recurrence and metastasis are the major causes of death in cancer patients. Biomarkers that can predict tumor recurrence in cancer patients who are in the early pathology stage and able to receive curative resection will greatly improve survival. To facilitate early cancer diagnosis and as a companion diagnostic to follow the efficacy of the therapy, such biomarkers should be detected not only in resected tumors, but also in serum to provide a non-invasive assay. Accumulating evidence suggest that carboxypeptidase E (CPE), along with its N-terminal truncated derivative, could serve as a powerful prognostic biomarker for predicting recurrence and survival. Over-expression of carboxypeptidase E (CPE) mRNA is common in many different human cancer types including metastatic cervical cancer, renal (clear cell) carcinoma, Ewing sarcoma, glioblastoma and various types of astrocytomas and oligodendrogliomas.

Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2016Liquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California,